Moderna share price and Q2 2022 results preview
How to trade Moderna shares as the company is set to release its second quarter (Q2) 2022 results on 3 August 2022.
When are Moderna’s results expected?
Moderna is set to release its Q2 2022 results on 3 August 2022. The results are for the fiscal quarter ending June 2022.
What is ‘The Street’s’ expectation for the Q2 2022 results?
‘The Street’ expectations for the upcoming results are as follows:
- Revenue of $4.065 billion : -6.63% year on year (YoY)
- Earnings per share (EPS): $4.55 (-29.59% YoY)
As new variants in the coronavirus, such as omicron and its subvariants, keep emerging and countries such as the UK have lowered the age of those eligible for a second booster vaccine to the over 50s, the demand for vaccines such as the strain-specific one Moderna is developing, remains high.
This increased demand, as well as the fact that when Moderna will begin selling its vaccines directly to pharmacies at much higher prices than it does for government bulk orders, has recently boosted the Moderna share price which, even though it is still down around 30% year-to-date (YTD), has risen by around 50% from its June lows.
If Western countries were to develop a strategy of annual Covid 19 strain-specific booster vaccinations, like the annual flu jab, Moderna, as one of the world’s largest coronavirus vaccine producers, should greatly benefit.
The combined flu/Covid-19 shot Moderna is currently working on may further boost its share price, as may its phase 3 trials on vaccines for the flu, cytomegalovirus (CMV), and respiratory syncytial virus (RSV) if they come to fruition, especially since vaccines for CMV and RSV don’t exist yet and would give Moderna the first-to-market advantage.
If, however, only the more at risk were to receive an annual booster shot and its three phase 3 trials were all come to nothing, demand for Moderna vaccines would be much lower. This is the main dilemma facing investors in Moderna shares.
How to trade Moderna into the results
Refinitiv data shows a consensus analyst rating of between ‘buy’ and ‘hold’ for Moderna – 2 strong buy, 7 buy, 10 hold and 1 sell - with the median of estimates suggesting a long-term price target of $199.00 for the share, roughly 20% higher than the current price (as of 26 July 2022).
IG sentiment data shows that 86% of clients with open positions on the share (as of 26 July 2022) expect the price to rise over the near term, while 14% of these clients expect the price to fall.
Technical outlook on Moderna share price
The Moderna share price has been trying to bottom out for the majority of this year but still trades around 30% lower YTD.
For a medium-term bottom formation to be confirmed, a rise and weekly Friday chart close above the March peak at $188.00 would need to be seen. If so, the 200-day simple moving average (SMA) and the 2021-to-2022 downtrend line at $195.93 to $198.6 would be in focus, a rise of around 20% from current levels (as of 26 July).
The technical signs of a medium-term bottom likely being seen are encouraging, though, since the Moderna share price successfully defended its March and May lows by dropping to $115.61 in June before embarking on an uptrend which has so far added around 50% to its value.
During July the Moderna share price has been trading sideways below its early-July high at $180.73 for several weeks but is being supported by its two-month uptrend line at $160.6 and the $155.93 mid-July low. While the next lower late-June low at $135.52 underpins, the June-to-July uptrend remains intact.
Failure at $135.52 on a daily chart closing basis would likely push the March, May and June lows at $122.01 to $115.61 to the fore with this major support zone then expected to give way to the minor psychological $100.00 mark.
- Moderna is set to release its Q2 2022 results on 3 August 2022
- Q2 2022 results are expected to show a YoY decrease in both revenue and EPS
- Annual Covid-19 booster shots, direct sales to pharmacies and successful phase 3 trials for the flu, CMV, and RSV may boost Moderna’s share price but booster shots only for the at risk and unsuccessful trials could decrease demand for the company’s vaccines
- Long-term broker consensus suggests the share to currently be split between a ‘buy’ and a ‘hold’, with a median price target of $199.00
- 86% of IG’s clients with open positions are long the share
- The Moderna share price has been trying to bottom out for much of this year and a technical bottoming formation would be confirmed by a weekly chart close above the March peak at $188.00
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Act on share opportunities today
Go long or short on thousands of international stocks with spread bets and CFDs.
- Get full exposure for a comparatively small deposit
- Trade on spreads from just 0.1%
- Get greater order book visibility with direct market access
See opportunity on a stock?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Take your position
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance – upgrade to a live account to take advantage.
- Trade a huge range of popular stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.